Muscle Spasticity Therapeutics Pipeline Review, H1 2015 offers “Muscle Spasticity – Pipeline Review, H1 2015”global research report on its store.

This report provides comprehensive information on the therapeutic development for Muscle Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available at .

Scope of The Report:

  • The report provides a snapshot of the global therapeutic landscape of Muscle Spasticity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Muscle Spasticity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Muscle Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Muscle Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy This Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Muscle Spasticity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Muscle Spasticity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a copy of this report at .

Table of Content for “Muscle Spasticity – Pipeline Review, H1 2015” research report includes:

Muscle Spasticity Overview 6

Therapeutics Development 7

Pipeline Products for Muscle Spasticity - Overview 7

Pipeline Products for Muscle Spasticity - Comparative Analysis 8

Muscle Spasticity - Therapeutics under Development by Companies 9

Muscle Spasticity - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Muscle Spasticity - Products under Development by Companies 13

Muscle Spasticity - Companies Involved in Therapeutics Development 14

Daewoong Pharmaceutical Co., Ltd. 14

Ipsen S.A. 15

OBI Pharma, Inc. 16

Sanochemia Pharmazeutika AG 17

Sun Pharma Advanced Research Company Ltd. 18

Muscle Spasticity - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

abobotulinumtoxin A - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

baclofen ER - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NB-2221 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

OBI-858 - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

onabotulinumtoxin A - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

tolperisone - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Muscle Spasticity - Recent Pipeline Updates 36

Muscle Spasticity - Dormant Projects 38

Muscle Spasticity - Discontinued Products 39

Muscle Spasticity - Product Development Milestones 40

Featured News & Press Releases 40

Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults 40

Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients 42

Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly 43

Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe 44

Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul 45

Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity 46

Priced at US $2000 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( ).